Skip to main content
Erschienen in:

01.06.2019 | Case report

Bufexamac/chlorhexidine/lidocaine

Allergic contact dermatitis: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Wong G, et al. Severe allergic contact dermatitis to topical bufexamac requiring hospitalisation. Australasian Journal of Dermatology 60 (Suppl. 1): 100-101, 14 May 2019. Available from: URL: http://doi.org/10.1111/ajd.13027 [abstract] -Australia Wong G, et al. Severe allergic contact dermatitis to topical bufexamac requiring hospitalisation. Australasian Journal of Dermatology 60 (Suppl. 1): 100-101, 14 May 2019. Available from: URL: http://​doi.​org/​10.​1111/​ajd.​13027 [abstract] -Australia
Metadaten
Titel
Bufexamac/chlorhexidine/lidocaine
Allergic contact dermatitis: case report
Publikationsdatum
01.06.2019
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-019-63631-5